Vera Therapeutics has submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgAN. The ORIGIN Phase 3 trial showed a 46% reduction in proteinuria compared to placebo at week 36. Atacicept targets both BAFF and APRIL, with potential FDA approval in 2026. The drug has received Breakthrough Therapy Designation. IgAN is a serious autoimmune disease that can lead to kidney failure. Atacicept is a self-administered once-weekly injection that inhibits B-cell production of autoantibodies. The ORIGIN 3 trial is ongoing, with completion expected in 2027. Vera Therapeutics aims to change the standard of care for IgAN patients.

Read more at GlobeNewswire: Vera Therapeutics Submits Biologics License Application to